Mumbai,  Pharma major Lupin on Monday announced that it has received an Establishment Inspection Report (EIR) from the US health regulator ‘Food and Drug Administration (FDA) for its manufacturing plant in Nagpur.

The inspection for the facility was carried out by The US Food and Drug Administration (FDA) between January 6-10 this year.

"We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites," said Nilesh Gupta, Managing Director, Lupin.

Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the US, India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

Lupin is the third largest pharmaceutical company in the US by prescriptions and in India by global revenues. The Company invests 9.6 per cent of its revenues on research and development.

It has 15 manufacturing sites and seven research centres, with more than 20,000 professionals working globally.